{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:56Z","timestamp":1793666756955,"version":"4.5.1"},"reference-count":249,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173426"],"award-info":[{"award-number":["82173426"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473533"],"award-info":[{"award-number":["82473533"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473559"],"award-info":[{"award-number":["82473559"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.autrev.2025.103753","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:13:33Z","timestamp":1737375213000},"page":"103753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Advances in RNA therapy for the treatment of autoimmune diseases"],"prefix":"10.1016","volume":"24","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0010","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J Int Assoc Phys AIDS Care"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0008-4182(05)80078-X","article-title":"Adamis targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration","volume":"40","author":"Ng","year":"2005","journal-title":"Can J Ophthalmol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0020","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"50","key":"10.1016\/j.autrev.2025.103753_bb0025","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 Vaccine - United States","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep 2020"},{"key":"10.1016\/j.autrev.2025.103753_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fgene.2015.00002","article-title":"Non-coding RNA: what is functional and what is junk?","volume":"6","author":"Palazzo","year":"2015","journal-title":"Front Genet"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1534\/genetics.112.146704","article-title":"Long noncoding RNAs: past, present, and future","volume":"193","author":"Kung","year":"2013","journal-title":"Genetics"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrg3722","article-title":"The rise of regulatory RNA","volume":"15","author":"Morris","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0045","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103777","article-title":"A guide to naming human non-coding RNA genes","volume":"39","author":"Seal","year":"2020","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0050","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s11011-021-00739-y","article-title":"Emerging role of non-coding RNA in health and disease","volume":"36","author":"Bhatti","year":"2021","journal-title":"Metab Brain Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0055","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0060","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ymthe.2020.12.022","article-title":"Clinical applications of single-stranded oligonucleotides: current landscape of approved and in-development therapeutics","volume":"29","author":"Scharner","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103753_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.molcel.2021.12.002","article-title":"The CRISPR-Cas toolbox and gene editing technologies","volume":"82","author":"Liu","year":"2022","journal-title":"Mol Cell"},{"issue":"4949 Pt 1","key":"10.1016\/j.autrev.2025.103753_bb0075","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103753_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2016.05.008","article-title":"Recent innovations in mRNA vaccines","volume":"41","author":"Ulmer","year":"2016","journal-title":"Curr Opin Immunol"},{"issue":"7006","key":"10.1016\/j.autrev.2025.103753_bb0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13046-021-02193-1","article-title":"Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics","volume":"40","author":"Cuciniello","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1101\/gr.6036807","article-title":"Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs","volume":"17","author":"Ponjavic","year":"2007","journal-title":"Genome Res"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0100","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1073\/pnas.0706729105","article-title":"Specific expression of long noncoding RNAs in the mouse brain","volume":"105","author":"Mercer","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"10.1016\/j.autrev.2025.103753_bb0105","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1101\/gad.17446611","article-title":"Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses","volume":"25","author":"Cabili","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/j.autrev.2025.103753_bb0110","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3389\/fphys.2018.01201","article-title":"Long non-coding RNA structure and function: Is there a link?","volume":"9","author":"Zampetaki","year":"2018","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","article-title":"Therapeutic targeting of long non-coding RNAs in cancer","volume":"24","author":"Arun","year":"2018","journal-title":"Trends Mol Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tips.2022.01.008","article-title":"The potential of long noncoding RNA therapies","volume":"43","author":"Mercer","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","article-title":"The expanding regulatory mechanisms and cellular functions of circular RNAs","volume":"21","author":"Chen","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0130","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.molcel.2013.08.017","article-title":"Circular intronic long noncoding RNAs","volume":"51","author":"Zhang","year":"2013","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","article-title":"Circular RNA: metabolism, functions and interactions with proteins","volume":"19","author":"Zhou","year":"2020","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41392-021-00569-5","article-title":"Targeting circular RNAs as a therapeutic approach: Current strategies and challenges","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"7857","key":"10.1016\/j.autrev.2025.103753_bb0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B1351 and B117","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2025.103753_bb0160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2014.08.015","article-title":"Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients","volume":"111","author":"van der Ree","year":"2014","journal-title":"Antivir Res"},{"issue":"13","key":"10.1016\/j.autrev.2025.103753_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137167","article-title":"MicroRNA-based diagnosis and therapy","volume":"23","author":"Ho","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"32","key":"10.1016\/j.autrev.2025.103753_bb0170","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1073\/pnas.1108567108","article-title":"Male germ cells express abundant endogenous siRNAs","volume":"108","author":"Song","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7194","key":"10.1016\/j.autrev.2025.103753_bb0175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature06908","article-title":"Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes","volume":"453","author":"Watanabe","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103753_bb0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.bioeng.8.061505.095848","article-title":"Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs","volume":"8","author":"Dykxhoorn","year":"2006","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.autrev.2025.103753_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2025.103753_bb0190","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: An emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0205","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/anie.202003563","article-title":"Nucleic acid aptamers for molecular diagnostics and therapeutics: Advances and perspectives","volume":"60","author":"Li","year":"2021","journal-title":"Angew Chem Int Ed Eng"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0210","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1021\/acsami.0c14788","article-title":"Recent developments in aptasensors for diagnostic applications","volume":"13","author":"Liu","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0215","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cbpa.2006.04.003","article-title":"Nucleic acid aptamers and enzymes as sensors","volume":"10","author":"Navani","year":"2006","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"10.1016\/j.autrev.2025.103753_bb0225","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1021\/acs.accounts.1c00541","article-title":"Therapeutic mRNA engineering from head to tail","volume":"54","author":"Jia","year":"2021","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.autrev.2025.103753_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2021.06.020","article-title":"Liu synthetic modified messenger RNA for therapeutic applications","volume":"131","author":"Gao","year":"2021","journal-title":"Acta Biomater"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0235","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"20","key":"10.1016\/j.autrev.2025.103753_bb0240","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2174\/0929867326666181126165139","article-title":"The role of mitochondria in systemic lupus erythematosus: A glimpse of various pathogenetic mechanisms","volume":"27","author":"Yang","year":"2020","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041270","article-title":"Crosstalk between MicroRNA and oxidative stress in physiology and pathology","volume":"21","author":"Fioravanti","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.autrev.2025.103753_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122660","article-title":"Could oxidative stress regulate the expression of MicroRNA-146a and MicroRNA-34a in human osteoarthritic chondrocyte cultures?","volume":"18","author":"Cheleschi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.26217","article-title":"Multiple functions of long non-coding RNAs in oxidative stress, DNA damage response and cancer progression","volume":"119","author":"Tehrani","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.autrev.2025.103753_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.012","article-title":"Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis","volume":"108","author":"Portal-N\u00fa\u00f1ez","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0265","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12967-018-1739-5","article-title":"NovelmiRNA-25 inhibits AMPD2 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and represents a promising novel biomarker","volume":"16","author":"Guo","year":"2018","journal-title":"J Transl Med"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0270","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.immuni.2013.02.021","article-title":"The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis","volume":"38","author":"Henao-Mejia","year":"2013","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.autrev.2025.103753_bb0275","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.15252\/embj.201489589","article-title":"Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation","volume":"34","author":"Warth","year":"2015","journal-title":"EMBO J"},{"issue":"Pt A","key":"10.1016\/j.autrev.2025.103753_bb0280","article-title":"MicroRNA-155 and antiviral immune responses","volume":"101","author":"Jafarzadeh","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12020362","article-title":"Sultanova from viral infection to autoimmune reaction: exploring the link between human herpesvirus 6 and autoimmune diseases","volume":"12","author":"Sokolovska","year":"2024","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102709","article-title":"The roles of adenosine deaminase in autoimmune diseases","volume":"20","author":"Gao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103753_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2789242","article-title":"Genetic factors of autoimmune diseases","volume":"2017","author":"Ceccarelli","year":"2017","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103753_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.autrev.2025.103753_bb0310","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.4049\/jimmunol.0904060","article-title":"MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1","volume":"184","author":"Pan","year":"2010","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0315","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1002\/jcb.29624","article-title":"Downregulation of microRNA-101-3p participates in systemic lupus erythematosus progression via negatively regulating HDAC9","volume":"121","author":"Sun","year":"2020","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0320","first-page":"823","article-title":"Regulation of dendritic cell activation by microRNA let-7c and BLIMP1","volume":"123","author":"Kim","year":"2013","journal-title":"J Clin Invest"},{"issue":"50","key":"10.1016\/j.autrev.2025.103753_bb0325","doi-asserted-by":"crossref","first-page":"20194","DOI":"10.1073\/pnas.1317632110","article-title":"Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse","volume":"110","author":"Thai","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.autrev.2025.103753_bb0330","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1038\/ncomms8096","article-title":"MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis","volume":"6","author":"Pan","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.autrev.2025.103753_bb0335","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nm.2815","article-title":"The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-\u03b1","volume":"18","author":"Zhu","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0340","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13075-019-2044-2","article-title":"LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration","volume":"21","author":"Luan","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0345","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.39485","article-title":"In vivo therapeutic success of MicroRNA-155 antagomir in a mouse model of lupus alveolar hemorrhage","volume":"68","author":"Zhou","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103753_bb0350","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3389\/fimmu.2019.02229","article-title":"MiRNA regulation of MIF in SLE and attenuation of murine lupus nephritis with miR-654","volume":"10","author":"Tu","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0355","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2533\/chimia.2020.798","article-title":"Discovery of small molecule drugs targeting the biogenesis of microRNA-155 for the treatment of systemic lupus erythematosus","volume":"74","author":"Azzaoui","year":"2020","journal-title":"Chimia (Aarau)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0360","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s10020-022-00493-6","article-title":"Hydroxychloroquine induces apoptosis of myeloid-derived suppressor cells via up-regulation of CD81 contributing to alleviate lupus symptoms","volume":"28","author":"Ni","year":"2022","journal-title":"Mol Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0365","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/imcb.12562","article-title":"Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammation","volume":"100","author":"Hasnat","year":"2022","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0370","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.41987","article-title":"Up-regulated interleukin-10 induced by E2F transcription factor 2-MicroRNA-17-5p circuitry in extrafollicular effector B cells contributes to autoantibody production in systemic lupus erythematosus","volume":"74","author":"Xu","year":"2022","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0375","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12967-021-02967-3","article-title":"tRNA derived fragment (tRF)-3009 participates in modulation of IFN-\u03b1-induced CD4(+) T cell oxidative phosphorylation in lupus patients","volume":"19","author":"Geng","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2025.103753_bb0380","article-title":"Therapeutic effects of cationic liposomes on lupus-prone MRL\/lpr mice are mediated via inhibition of TLR4-triggered B-cell activation","volume":"40","author":"Diao","year":"2022","journal-title":"Nanomedicine"},{"key":"10.1016\/j.autrev.2025.103753_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120529","article-title":"Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: A possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies","volume":"601","author":"Takata","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.autrev.2025.103753_bb0390","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cellimm.2017.06.004","article-title":"Comprehensive long non-coding RNA expression profiling reveals their potential roles in systemic lupus erythematosus","volume":"319","author":"Li","year":"2017","journal-title":"Cell Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0395","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13167","article-title":"Long non-coding RNAs in systemic lupus erythematosus: New insights into disease pathogenesis and diagnosis","volume":"95","author":"Chen","year":"2022","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0400","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/rheumatology\/keaa575","article-title":"Long non-coding RNA expression profiles in neutrophils revealed potential biomarker for prediction of renal involvement in SLE patients","volume":"60","author":"Cai","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0405","doi-asserted-by":"crossref","first-page":"349","DOI":"10.21037\/atm.2020.03.25","article-title":"Comprehensive expression profile of long non-coding RNAs in Peripheral blood mononuclear cells from patients with neuropsychiatric systemic lupus erythematosus","volume":"8","author":"Geng","year":"2020","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0410","first-page":"3489","article-title":"Integrative analysis of long non-coding RNAs and messenger RNA expression profiles in systemic lupus erythematosus","volume":"17","author":"Luo","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2025.103753_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.792884","article-title":"LncRNA expression profiles in systemic lupus erythematosus and rheumatoid arthritis: Emerging biomarkers and therapeutic targets","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0420","first-page":"163","article-title":"Role of circular RNAs in immune-related diseases","volume":"42","author":"Zhan","year":"2022","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0425","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s10067-018-4392-8","article-title":"Microarray expression profile of circular RNAs and mRNAs in children with systemic lupus erythematosus","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0430","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12108","article-title":"Hsa_circ_0010957 level is increased and sponges microRNA-125b in CD4(+) T cells of patients with systemic lupus erythematosus","volume":"23","author":"He","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2025.103753_bb0435","article-title":"Current understanding of circular RNAs in systemic lupus erythematosus","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103753_bb0440","doi-asserted-by":"crossref","unstructured":"Ouyang, Q., Q. Huang, Z. Jiang, J. Zhao, G.P. Shi, and M. Yang Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis. https:\/\/doi.org\/10.1016\/j.molimm.2018.07.029 Mol Immunol 2018. 101 p. 531-538.","DOI":"10.1016\/j.molimm.2018.07.029"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0445","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-018-1618-8","article-title":"CircIBTK inhibits DNA demethylation and activation of AKT signaling pathway via miR-29b in peripheral blood mononuclear cells in systemic lupus erythematosus","volume":"20","author":"Wang","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0450","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/imm.12940","article-title":"Circular RNA expression profile and potential function of hsa_circ_0045272 in systemic lupus erythematosus","volume":"155","author":"Li","year":"2018","journal-title":"Immunology"},{"issue":"21","key":"10.1016\/j.autrev.2025.103753_bb0455","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1042\/CS20180403","article-title":"The down-regulation of hsa_circ_0012919, the sponge for miR-125a-3p, contributes to DNA methylation of CD11a and CD70 in CD4(+) T cells of systemic lupus erythematous","volume":"132","author":"Zhang","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.autrev.2025.103753_bb0460","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jconrel.2021.08.040","article-title":"Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity","volume":"339","author":"Parayath","year":"2021","journal-title":"J Control Release"},{"issue":"482","key":"10.1016\/j.autrev.2025.103753_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0470","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0475","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0480","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0485","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3066","article-title":"Optimization of electroporation and other non-viral gene delivery strategies for T cells","volume":"37","author":"Harris","year":"2021","journal-title":"Biotechnol Prog"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0490","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12885-017-3539-3","article-title":"RNA-transfection of \u03b3\/\u03b4 T cells with a chimeric antigen receptor or an \u03b1\/\u03b2 T-cell receptor: A safer alternative to genetically engineered \u03b1\/\u03b2 T cells for the immunotherapy of melanoma","volume":"17","author":"Harrer","year":"2017","journal-title":"BMC Cancer"},{"issue":"6576","key":"10.1016\/j.autrev.2025.103753_bb0495","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0500","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/gt.2008.189","article-title":"Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer","volume":"16","author":"Birkholz","year":"2009","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0505","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2025.103753_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J Autoimmun"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103753_bb0515","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00005-016-0443-5","article-title":"Significance of polymorphism and expression of miR-146a and NFkB1 genetic variants in patients with rheumatoid arthritis","volume":"64","author":"Bogunia-Kubik","year":"2016","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0520","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13075-016-1085-z","article-title":"Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis? 10.1186\/s13075-016-1085-z","volume":"18","author":"Cuppen","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030452","article-title":"miRNAs as biomarkers and possible therapeutic strategies in rheumatoid arthritis","volume":"11","author":"Kmio\u0142ek","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0530","article-title":"Plasma miRNA profile of Crohn's disease and rheumatoid arthritis patients","volume":"11","author":"Saccon","year":"2022","journal-title":"Biology (Basel)"},{"issue":"11","key":"10.1016\/j.autrev.2025.103753_bb0535","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1093\/rheumatology\/keab407","article-title":"Comprehensive microRNA and transcriptomic profiling of rheumatoid arthritis monocytes: role of microRNA-146b in pro-inflammatory progression","volume":"60","author":"Ciechomska","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103753_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.633201","article-title":"Serum miRNA signature in rheumatoid arthritis and \"At-Risk Individuals\"","volume":"12","author":"Cunningham","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0545","article-title":"Differential expression profiles of the transcriptome and miRNA interactome in synovial fibroblasts of rheumatoid arthritis revealed by next generation sequencing","volume":"9","author":"Tseng","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.autrev.2025.103753_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12970","article-title":"MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis","volume":"7","author":"Alivernini","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103753_bb0555","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.2147\/DDDT.S177128","article-title":"miR-708-5p promotes fibroblast-like synoviocytes' cell apoptosis and ameliorates rheumatoid arthritis by the inhibition of Wnt3a\/\u03b2-catenin pathway","volume":"12","author":"Wu","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0560","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-019-1920-0","article-title":"miR-449a inhibits cell proliferation, migration, and inflammation by regulating high-mobility group box protein 1 and forms a mutual inhibition loop with Yin Yang 1 in rheumatoid arthritis fibroblast-like synoviocytes","volume":"21","author":"Cai","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"11-12","key":"10.1016\/j.autrev.2025.103753_bb0565","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10495-018-1474-7","article-title":"MiRNA-126 expression inhibits IL-23R mediated TNF-\u03b1 or IFN-\u03b3 production in fibroblast-like synoviocytes in a mice model of collagen-induced rheumatoid arthritis","volume":"23","author":"Gao","year":"2018","journal-title":"Apoptosis"},{"key":"10.1016\/j.autrev.2025.103753_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106067","article-title":"Up-regulation of miR-365 promotes the apoptosis and restrains proliferation of synoviocytes through downregulation of IGF1 and the inactivation of the PI3K\/AKT\/mTOR pathway in mice with rheumatoid arthritis","volume":"79","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0575","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-020-2133-2","article-title":"Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA-146a-5p in rheumatoid arthritis","volume":"22","author":"Sun","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.autrev.2025.103753_bb0580","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.7150\/thno.45214","article-title":"Identification of a novel microRNA-141-3p\/Forkhead box C1\/\u03b2-catenin axis associated with rheumatoid arthritis synovial fibroblast function in vivo and in vitro","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0585","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.4049\/jimmunol.1800304","article-title":"Therapeutic potential of mesenchymal cell-derived miRNA-150-5p-expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF","volume":"201","author":"Chen","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103753_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105985","article-title":"Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis","volume":"78","author":"Zheng","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0595","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11926-021-01009-7","article-title":"Exogenous miRNA: A perspective role as therapeutic in rheumatoid arthritis","volume":"23","author":"Saquib","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0600","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/annrheumdis-2022-222228","article-title":"Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and\/or anti-TNF\u03b1 therapy: a placebo-controlled phase II study","volume":"81","author":"Daien","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2025.103753_bb0605","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/annrheumdis-2018-213103","article-title":"Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis","volume":"77","author":"Bustamante","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0610","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.41748","article-title":"Notch-1 and Notch-3 mediate hypoxia-induced activation of synovial fibroblasts in rheumatoid arthritis","volume":"73","author":"Chen","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0615","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.20975","article-title":"Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis","volume":"52","author":"Schiffelers","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"15","key":"10.1016\/j.autrev.2025.103753_bb0620","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1039\/D0NR00454E","article-title":"A novel indomethacin\/methotrexate\/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis","volume":"12","author":"Yin","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.autrev.2025.103753_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106933","article-title":"Nanoparticle-facilitated delivery of BAFF-R siRNA for B cell intervention and rheumatoid arthritis therapy","volume":"88","author":"Wu","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0630","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s13346-021-01037-x","article-title":"Nanomedicine-based combination of dexamethasone palmitate and MCL-1 siRNA for synergistic therapeutic efficacy against rheumatoid arthritis","volume":"11","author":"Li","year":"2021","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010162","article-title":"Efficient treatment of rheumatoid arthritis by degradable LPCE nano-conjugate-delivered p65 siRNA","volume":"14","author":"Chen","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0640","first-page":"5965","article-title":"Comprehensive analysis of long non-coding RNA and mRNA expression profiles in rheumatoid arthritis","volume":"14","author":"Luo","year":"2017","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0645","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.gene.2016.08.012","article-title":"LncRNAs expression in adjuvant-induced arthritis rats reveals the potential role of LncRNAs contributing to rheumatoid arthritis pathogenesis","volume":"593","author":"Jiang","year":"2016","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0650","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10787-019-00666-6","article-title":"Analysis of lncRNA expression profiles by sequencing reveals that lnc-AL928768.3 and lnc-AC091493.1 are novel biomarkers for disease risk and activity of rheumatoid arthritis","volume":"28","author":"Sun","year":"2020","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.autrev.2025.103753_bb0655","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ebiom.2019.11.024","article-title":"LncRNA PICSAR promotes cell proliferation, migration and invasion of fibroblast-like synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis","volume":"50","author":"Bi","year":"2019","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0660","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s12026-015-8756-8","article-title":"Increased expression of long noncoding RNAs LOC100652951 and LOC100506036 in T cells from patients with rheumatoid arthritis facilitates the inflammatory responses","volume":"64","author":"Lu","year":"2016","journal-title":"Immunol Res"},{"issue":"7","key":"10.1016\/j.autrev.2025.103753_bb0665","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41419-019-1744-5","article-title":"Roles of circular RNAs in immune regulation and autoimmune diseases","volume":"10","author":"Zhou","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2025.103753_bb0670","article-title":"Functional interactions between lncRNAs\/circRNAs and miRNAs: Insights into rheumatoid arthritis","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0675","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.3892\/mmr.2017.7638","article-title":"Circular RNA expression profiles of peripheral blood mononuclear cells in rheumatoid arthritis patients, based on microarray chip technology","volume":"16","author":"Zheng","year":"2017","journal-title":"Mol Med Rep"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0680","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193160","article-title":"RNA-seq reveals the circular RNA and miRNA expression profile of peripheral blood mononuclear cells in patients with rheumatoid arthritis","volume":"40","author":"Wen","year":"2020","journal-title":"Biosci Rep"},{"key":"10.1016\/j.autrev.2025.103753_bb0685","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fimmu.2019.00639","article-title":"Roles of CircRNAs in autoimmune diseases","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103753_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.628654","article-title":"Circ_0088194 promotes the invasion and migration of rheumatoid arthritis fibroblast-like synoviocytes via the miR-766-3p\/MMP2 axis","volume":"12","author":"Cai","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0695","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13018-021-02306-8","article-title":"Circ-AFF2\/miR-650\/CNP axis promotes proliferation, inflammatory response, migration, and invasion of rheumatoid arthritis synovial fibroblasts","volume":"16","author":"Qu","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"12","key":"10.1016\/j.autrev.2025.103753_bb0700","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/15384101.2021.1916272","article-title":"Chen Hsa_circ_0044235 regulates the pyroptosis of rheumatoid arthritis via MiR-135b-5p-SIRT1 axis","volume":"20","author":"Chen","year":"2021","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0705","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10753-021-01538-4","article-title":"Circular RNA circ_0008360 inhibits the proliferation, migration, and inflammation and promotes apoptosis of fibroblast-like synoviocytes by regulating miR-135b-5p\/HDAC4 axis in rheumatoid arthritis","volume":"45","author":"Hao","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.autrev.2025.103753_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.722017","article-title":"Identification of circular RNAs Circ_0005008 and Circ_0005198 in plasma as novel biomarkers for new-onset rheumatoid arthritis","volume":"12","author":"Ouyang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103753_bb0715","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9412387","article-title":"Hsa_circ_0001859 regulates ATF2 expression by functioning as an MiR-204\/211 sponge in human rheumatoid arthritis","volume":"2018","author":"Li","year":"2018","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0720","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41419-020-03038-z","article-title":"CircRNA_09505 aggravates inflammation and joint damage in collagen-induced arthritis mice via miR-6089\/AKT1\/NF-\u03baB axis","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2025.103753_bb0725","article-title":"Angiogenesis is inhibited by arsenic trioxide through downregulation of the CircHIPK3\/miR-149-5p\/FOXO1\/VEGF functional module in rheumatoid arthritis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103753_bb0730","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.2147\/IJN.S333465","article-title":"Therapeutic potential of exosomal circRNA derived from synovial mesenchymal cells via targeting circEDIL3\/miR-485-3p\/PIAS3\/STAT3\/VEGF functional module in rheumatoid arthritis","volume":"16","author":"Zhang","year":"2021","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"10.1016\/j.autrev.2025.103753_bb0735","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/1529-0131(199707)40:7<1292::AID-ART14>3.0.CO;2-8","article-title":"Inhibition of rheumatoid synovial fibroblast proliferation by antisense oligonucleotides targeting proliferating cell nuclear antigen messenger RNA","volume":"40","author":"Morita","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0740","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1124\/jpet.102.036749","article-title":"Phase I trial of ISIS 104838, a 2\u2019-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha","volume":"303","author":"Sewell","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031022","article-title":"Anti-rheumatic effect of antisense oligonucleotide Cytos-11 targeting TNF-\u03b1 expression","volume":"22","author":"Makalish","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0750","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4049\/immunohorizons.2000108","article-title":"Potent and selective knockdown of tyrosine kinase 2 by antisense oligonucleotides","volume":"5","author":"Tran","year":"2021","journal-title":"Immunohorizons"},{"key":"10.1016\/j.autrev.2025.103753_bb0755","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa","year":"2022","journal-title":"Annu Rev Pathol"},{"issue":"21","key":"10.1016\/j.autrev.2025.103753_bb0760","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111887","article-title":"Circulating miRNAs as potential biomarkers distinguishing relapsing-remitting from secondary progressive multiple sclerosis. A review","volume":"22","author":"Pietrasik","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0765","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.5399","article-title":"MicroRNAs in gray and white matter multiple sclerosis lesions: impact on pathophysiology","volume":"250","author":"Teuber-Hanselmann","year":"2020","journal-title":"J Pathol"},{"issue":"22","key":"10.1016\/j.autrev.2025.103753_bb0770","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.1158\/0008-5472.CAN-07-1484","article-title":"Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway","volume":"67","author":"Ovcharenko","year":"2007","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.autrev.2025.103753_bb0775","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1177\/1352458513490542","article-title":"Differential microRNA expression in blood in multiple sclerosis","volume":"19","author":"S\u00f8ndergaard","year":"2013","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0780","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4103\/1673-5374.266905","article-title":"MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression","volume":"15","author":"Martinez","year":"2020","journal-title":"Neural Regen Res"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0785","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.23880","article-title":"Circulating microRNAs as biomarkers for disease staging in multiple sclerosis","volume":"73","author":"Gandhi","year":"2013","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0790","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1212\/NXI.0000000000000267","article-title":"Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis","volume":"3","author":"Regev","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0795","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1007\/s12035-022-02854-y","article-title":"The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis","volume":"59","author":"Nowak","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb0800","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.4103\/1673-5374.280307","article-title":"MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis","volume":"15","author":"Martinez","year":"2020","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0805","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1523\/JNEUROSCI.2666-17.2017","article-title":"CaMKII\u03b1 mediates the effect of IL-17 To promote ongoing spontaneous and evoked pain in multiple sclerosis","volume":"38","author":"Hu","year":"2018","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0810","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13105-018-00660-6","article-title":"LINGO-1 siRNA nanoparticles promote central remyelination in ethidium bromide-induced demyelination in rats","volume":"75","author":"Youssef","year":"2019","journal-title":"J Physiol Biochem"},{"issue":"9","key":"10.1016\/j.autrev.2025.103753_bb0815","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.4103\/1673-5374.306061","article-title":"What do we know about the role of lncRNAs in multiple sclerosis?","volume":"16","author":"Nociti","year":"2021","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.autrev.2025.103753_bb0820","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jneuroim.2018.08.008","article-title":"LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients","volume":"324","author":"Fenoglio","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103753_bb0825","doi-asserted-by":"crossref","first-page":"22153","DOI":"10.1002\/jcp.28779","article-title":"LncRNAs associated with multiple sclerosis expressed in the Th1 cell lineage","volume":"234","author":"Hosseini","year":"2019","journal-title":"J Cell Physiol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103753_bb0830","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1021\/acschemneuro.0c00150","article-title":"LncRNA GAS5 and miR-137 polymorphisms and expression are associated with multiple sclerosis risk: mechanistic insights and potential clinical impact","volume":"11","author":"Senousy","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.autrev.2025.103753_bb0835","article-title":"OIP5-AS1 facilitates Th17 differentiation and EAE severity by targeting miR-140-5p to regulate RhoA\/ROCK2 signaling pathway","author":"Liu","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.autrev.2025.103753_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116731","article-title":"Down-regulation of taurine-up-regulated gene 1 attenuates inflammation by sponging miR-9-5p via targeting NF-\u03baB1\/p50 in multiple sclerosis","volume":"233","author":"Yue","year":"2019","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0845","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12974-021-02156-5","article-title":"IL-9-triggered lncRNA Gm13568 regulates Notch1 in astrocytes through interaction with CBP\/P300: contribute to the pathogenesis of experimental autoimmune encephalomyelitis","volume":"18","author":"Liu","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"11","key":"10.1016\/j.autrev.2025.103753_bb0850","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/glia.24239","article-title":"The LncRNA AK018453 regulates TRAP1\/Smad signaling in IL-17-activated astrocytes: A potential role in EAE pathogenesis","volume":"70","author":"Zhang","year":"2022","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0855","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030576","article-title":"The characterization of GSDMB splicing and backsplicing profiles identifies novel isoforms and a circular RNA that are dysregulated in multiple sclerosis","volume":"18","author":"Cardamone","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0860","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001041","article-title":"Multiple sclerosis: circRNA profile defined reveals links to b-cell function","volume":"8","author":"Zurawska","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103753_bb0865","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.875994","article-title":"Impact of diminished expression of circRNA on multiple sclerosis pathomechanisms","volume":"13","author":"Mycko","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103753_bb0870","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121850","article-title":"Profiling of plasma extracellular vesicle transcriptome reveals that circRNAs are prevalent and differ between multiple sclerosis patients and healthy controls","volume":"9","author":"Iparraguirre","year":"2021","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.autrev.2025.103753_bb0875","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41423-021-00748-y","article-title":"The circular RNA circINPP4B acts as a sponge of miR-30a to regulate Th17 cell differentiation during progression of experimental autoimmune encephalomyelitis","volume":"18","author":"Han","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"6525","key":"10.1016\/j.autrev.2025.103753_bb0880","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb0885","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41409-020-0826-4","article-title":"The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus","volume":"55","author":"Passweg","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb0890","article-title":"Immune checkpoint ligand bioengineered schwann cells as antigen-specific therapy for experimental autoimmune encephalomyelitis","volume":"34","author":"Au","year":"2022","journal-title":"Adv Mater"},{"key":"10.1016\/j.autrev.2025.103753_bb0895","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103753_bb0900","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1431349","article-title":"GDNF enhances therapeutic efficiency of neural stem cells-based therapy in chronic experimental allergic encephalomyelitis in rat","volume":"2016","author":"Gao","year":"2016","journal-title":"Stem Cells Int"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0905","first-page":"46","article-title":"Co-transplantation of human neurotrophic factor secreting cells and adipose-derived stem cells in rat model of multiple sclerosis","volume":"20","author":"Razavi","year":"2018","journal-title":"Cell J"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0910","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1038\/s41467-021-26902-8","article-title":"DNA\/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo","volume":"12","author":"Ohyagi","year":"2021","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.autrev.2025.103753_bb0915","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/WNL.0000000000000926","article-title":"CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS","volume":"83","author":"Limmroth","year":"2014","journal-title":"Neurology"},{"issue":"10281","key":"10.1016\/j.autrev.2025.103753_bb0920","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0925","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/JID.2015.409","article-title":"microRNAs in psoriasis","volume":"136","author":"Hawkes","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103753_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102472","article-title":"Utility of circulating serum miRNA profiles to evaluate the potential risk and severity of immune-mediated inflammatory disorders","volume":"111","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2020","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.04.021","article-title":"miRNA profiling of extracellular vesicles reveals biomarkers for psoriasis","volume":"141","author":"Wang","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103753_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102614","article-title":"Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities","volume":"118","author":"Srivastava","year":"2021","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0945","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/exd.14497","article-title":"MicroRNA profiling of psoriatic skin identifies 11 miRNAs associated with disease severity","volume":"31","author":"Solvin","year":"2022","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0950","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/bjd.21232","article-title":"miR-378a regulates keratinocyte responsiveness to interleukin-17A in psoriasis","volume":"187","author":"Xia","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb0955","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtv.2021.08.006","article-title":"Lin MiR-15a-5p targets FOSL1 to inhibit proliferation and promote apoptosis of keratinocytes via MAPK\/ERK pathway","volume":"30","author":"Meng","year":"2021","journal-title":"J Tissue Viability"},{"issue":"11","key":"10.1016\/j.autrev.2025.103753_bb0960","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41419-021-04230-5","article-title":"MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes","volume":"12","author":"Huang","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2025.103753_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107587","article-title":"miR-383 reduces keratinocyte proliferation and induces the apoptosis in psoriasis via disruption of LCN2-dependent JAK\/STAT pathway activation","volume":"96","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103753_bb0970","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/exd.14188","article-title":"MicroRNA-215-5p inhibits the proliferation of keratinocytes and alleviates psoriasis-like inflammation by negatively regulating DYRK1A and its downstream signalling pathways","volume":"30","author":"Liu","year":"2021","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0975","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jaci.2020.12.657","article-title":"Cross-talk between IFN-\u03b3 and TWEAK through miR-149 amplifies skin inflammation in psoriasis","volume":"147","author":"Srivastava","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb0980","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jid.2020.07.009","article-title":"Small extracellular vesicles containing miR-381-3p from keratinocytes promote T Helper Type 1 and T Helper Type 17 polarization in psoriasis","volume":"141","author":"Jiang","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb0985","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1172\/JCI97426","article-title":"MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation","volume":"128","author":"Wu","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb0990","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1346-8138.15149","article-title":"Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice","volume":"47","author":"Feng","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2025.103753_bb0995","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2018.05.040","article-title":"Ultrasound targeting of Q-starch\/miR-197 complexes for topical treatment of psoriasis","volume":"284","author":"Lifshiz Zimon","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.autrev.2025.103753_bb1000","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714274","article-title":"ULK1 inhibition as a targeted therapeutic strategy for psoriasis by regulating keratinocytes and their crosstalk with neutrophils","volume":"12","author":"Qiu","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb1005","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/15592294.2020.1814486","article-title":"CYP2S1 might regulate proliferation and immune response of keratinocyte in psoriasis","volume":"16","author":"Sheng","year":"2021","journal-title":"Epigenetics"},{"key":"10.1016\/j.autrev.2025.103753_bb1010","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3389\/fimmu.2019.01268","article-title":"Thrombospondin-1\/CD47 interaction regulates Th17 and Treg differentiation in psoriasis","volume":"10","author":"Rodr\u00edguez-Jim\u00e9nez","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb1015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jid.2018.07.046","article-title":"Potentiation of psoriasis-like inflammation by PCSK9","volume":"139","author":"Luan","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2025.103753_bb1020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jconrel.2022.05.032","article-title":"Laser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis","volume":"347","author":"Lee","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.autrev.2025.103753_bb1025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2021.08.039","article-title":"Bentley TNF\u03b1 siRNA delivery by nanoparticles and photochemical internalization for psoriasis topical therapy","volume":"338","author":"Suzuki","year":"2021","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb1030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s13346-020-00723-6","article-title":"Nanostructured lipid carrier co-delivering tacrolimus and TNF-\u03b1 siRNA as an innovate approach to psoriasis","volume":"10","author":"Viegas","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.autrev.2025.103753_bb1035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2017.10.034","article-title":"Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis","volume":"268","author":"Nemati","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.autrev.2025.103753_bb1040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2016.05.017","article-title":"Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment","volume":"246","author":"Boakye","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.autrev.2025.103753_bb1045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejpb.2016.05.012","article-title":"RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase","volume":"105","author":"Depieri","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.autrev.2025.103753_bb1050","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11018","article-title":"Integrated analysis of immune-related long noncoding RNAs as diagnostic biomarkers in psoriasis","volume":"9","author":"Fan","year":"2021","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1055","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1186\/s12864-016-3188-y","article-title":"Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs","volume":"17","author":"Ahn","year":"2016","journal-title":"BMC Genomics"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb1060","first-page":"3421","article-title":"Long noncoding RNA expression profile and functional analysis in psoriasis","volume":"19","author":"Yan","year":"2019","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2025.103753_bb1065","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3389\/fimmu.2017.01053","article-title":"PRINS non-coding RNA regulates nucleic acid-induced innate immune responses of human keratinocytes","volume":"8","author":"Danis","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103753_bb1070","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3389\/fimmu.2018.01533","article-title":"Long non-coding RNAs play a role in the pathogenesis of psoriatic arthritis by regulating MicroRNAs and genes involved in inflammation and metabolic syndrome","volume":"9","author":"Dolcino","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40659-018-0181-8","article-title":"Knockdown of lncRNA MIR31HG inhibits cell proliferation in human HaCaT keratinocytes","volume":"51","author":"Gao","year":"2018","journal-title":"Biol Res"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb1080","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/exd.13890","article-title":"Mesenchymal stem cells in psoriatic lesions affect the skin microenvironment through circular RNA","volume":"28","author":"Liu","year":"2019","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1085","first-page":"174","article-title":"High-throughput RNA sequencing from paired lesional- and non-lesional skin reveals major alterations in the psoriasis circRNAome","volume":"12","author":"Moldovan","year":"2019","journal-title":"BMC Med Genet"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb1090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105182","article-title":"Canonical and interior circular RNAs function as competing endogenous RNAs in psoriatic skin","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb1095","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/exd.14227","article-title":"Characterization of circular RNA transcriptomes in psoriasis and atopic dermatitis reveals disease-specific expression profiles","volume":"30","author":"Moldovan","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2025.103753_bb1100","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.omtn.2020.08.001","article-title":"hsa_circ_0003738 inhibits the suppressive function of tregs by targeting miR-562\/IL-17A and miR-490-5p\/IFN-\u03b3 signaling pathway","volume":"21","author":"Yang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1105","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20203130","article-title":"Circ_0061012 contributes to IL-22-induced proliferation, migration and invasion in keratinocytes through miR-194-5p\/GAB1 axis in psoriasis","volume":"41","author":"He","year":"2021","journal-title":"Biosci Rep"},{"issue":"6","key":"10.1016\/j.autrev.2025.103753_bb1110","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jaci.2021.11.024","article-title":"Hsa_circ_0004287 inhibits macrophage-mediated inflammation in an N(6)-methyladenosine-dependent manner in atopic dermatitis and psoriasis","volume":"149","author":"Yang","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103753_bb1115","first-page":"1145","article-title":"CircEIF5 contributes to hyperproliferation and inflammation of keratinocytes in psoriasis via p-NF\u03baB and p-STAT3 signalling pathway","volume":"31","author":"Chen","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2025.103753_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120601","article-title":"Kogure Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF-\u03baB decoy oligodeoxynucleotide","volume":"602","author":"Fukuta","year":"2021","journal-title":"Int J Pharm"},{"issue":"7242","key":"10.1016\/j.autrev.2025.103753_bb1125","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/nature07774","article-title":"Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation","volume":"458","author":"Aouadi","year":"2009","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.autrev.2025.103753_bb1130","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmat2859","article-title":"Orally delivered thioketal nanoparticles loaded with TNF-\u03b1-siRNA target inflammation and inhibit gene expression in the intestines","volume":"9","author":"Wilson","year":"2010","journal-title":"Nat Mater"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/mt.2013.214","article-title":"Targeting intestinal inflammation with CD98 siRNA\/PEI-loaded nanoparticles","volume":"22","author":"Laroui","year":"2014","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2025.103753_bb1140","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1038\/ctg.2011.1","article-title":"Dual TNF-\u03b1\/Cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease","volume":"2","author":"Kriegel","year":"2011","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb1145","doi-asserted-by":"crossref","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","article-title":"Mongersen (GED-0301) for active crohn's disease: Results of a phase 3 study","volume":"115","author":"Sands","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2025.103753_bb1150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fphar.2019.00314","article-title":"Oligonucleotides-A novel promising therapeutic option for IBD","volume":"10","author":"Scarozza","year":"2019","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb1155","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801389","article-title":"Orally delivered antisense oligodeoxyribonucleotides of TNF-\u03b1 via polysaccharide-based nanocomposites targeting intestinal inflammation","volume":"8","author":"Duan","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.autrev.2025.103753_bb1160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.04.001","article-title":"Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing","volume":"132","author":"Rabbani","year":"2017","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb1165","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/wound.2011.0322","article-title":"Improving wound healing with topical gene therapy","volume":"1","author":"Layliev","year":"2012","journal-title":"Adv Wound Care (New Rochelle)"},{"issue":"18","key":"10.1016\/j.autrev.2025.103753_bb1170","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1073\/pnas.1505951112","article-title":"siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown","volume":"112","author":"Randeria","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.autrev.2025.103753_bb1175","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.molmet.2017.06.012","article-title":"Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes","volume":"6","author":"Neumann","year":"2017","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb1180","doi-asserted-by":"crossref","first-page":"E1137","DOI":"10.1152\/ajpendo.00158.2009","article-title":"Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes","volume":"297","author":"Saberi","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.autrev.2025.103753_bb1185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","article-title":"Complement C2 siRNA mediated therapy of myasthenia gravis in mice","volume":"42","author":"Huda","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103753_bb1190","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/nat.2020.0891","article-title":"Antisense oligonucleotides as potential therapeutics for Type 2 diabetes","volume":"31","author":"Chen","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.autrev.2025.103753_bb1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102982","article-title":"Non-coding RNAs in immunoregulation and autoimmunity: technological advances and critical limitations","volume":"134","author":"Kumar","year":"2023","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2025.103753_bb1205","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103753_bb1210","first-page":"12","article-title":"miRNA-mediated control of B cell responses in immunity and SLE","author":"Schell","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103753_bb1215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imm.12390","article-title":"MicroRNAs affect dendritic cell function and phenotype","volume":"144","author":"Smyth","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2025.103753_bb1220","first-page":"11","article-title":"MicroRNAs associated with a good prognosis of acute myeloid leukemia and their effect on macrophage polarization","author":"Neaga","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103753_bb1225","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/cbdd.12993","article-title":"Therapeutic potential of chemically modified siRNA: Recent trends","volume":"90","author":"Selvam","year":"2017","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103753_bb1235","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12943-023-01807-w","article-title":"The use of RNA-based treatments in the field of cancer immunotherapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer"},{"issue":"21","key":"10.1016\/j.autrev.2025.103753_bb1240","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1021\/acs.accounts.1c00521","article-title":"Immunogenicity of in vitro-transcribed RNA","volume":"54","author":"Mu","year":"2021","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.autrev.2025.103753_bb1245","article-title":"Antigen-specific immunotherapies for autoimmune disease","author":"Buckner","year":"2024","journal-title":"Nat Rev Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T08:37:41Z","timestamp":1740904661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":249,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1568997225000138"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103753","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in RNA therapy for the treatment of autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103753"}}